Please login to the form below

Not currently logged in
Email:
Password:

INC Research expands Asian presence with South Korea facility

New Seoul office will focus on study start-up and clinical operations

INC Research has expanded its Asian operations, opening a new office in Seoul that will focus on study start-up and clinical operation activities.

It will be managed by Dr Jessica Liu, general manager, and Lee Sun-Mee, associate director of clinical operations and site head for South Korea, and concentrate on increasing access to patients and improving clinical trial efficiency.

The contract research organisation's (CRO) move was prompted by government efforts that have seen infrastructure improvements, including the setting up of centres of excellence for clinical trials, and a streamlining of regulatory pathways.

Kelvin Logan, president Asia/Pacific at INC Research, said: "The South Korean government has renewed its focus on healthcare and clinical development leading to a dramatic increase in the opportunities for biopharmaceutical companies' drug development programmes.

"Our expanded team is equipped to help customers take advantage of the benefits of conducting clinical trials in this region, while navigating through the developing regulatory environment and leveraging support resources."

The country's pharmaceutical market has seen five years of double-digit growth and South Korea is considered the fastest-growing developed country by IMS Health.

Although healthcare spending in general is low compared to other OECD nations, pharma expenditure is around 24 per cent of the total national health insurance system's bill.

The new office adds to INC Research's existing bases across Asia in countries such as China, India, the Philippines and Thailand.

17th September 2012

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics